The subject of this publication is the conclusion of agreements pursuant to Section 130a (8) SGB V on various active substances / combinations of active substances in the context of an open house procedure. For details, see the relevant lot.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active substances/drug combinations within the framework of a so-called open house procedure. Under specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to conclude or join a discount contract in accordance with Section 130a (8) SGB V for the above-mentioned active substance/active ingredient combination. After registration, interested pharmaceutical companies can download the procurement documents (participation documents and contract) at: https://www.dtvp.de/Satellite/notice/documents.

The procedures referred to in Section I: Contracting authorities, item 1.3.) Communication for the purpose of unrestricted and complete, toll-free access to the order documents does not exist. Information can only be obtained via your registration on the “DTVP” award platform, under the communication tab. Information and answers about other bodies are not binding.

A prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the required procedural documents completely completed and signed. Any pharmaceutical company that meets the eligibility requirements and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. Accession or conclusion of the contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The contract can only start on the first day of each month. The earliest start date of the contract is 01.08.2023. Based on this, the contract period is a maximum of 24 months. The contract ends no later than 31.07.2025, regardless of the date of conclusion of the contract. The offer must be available by 23.06.2023 at the latest if the contract starts on 01.08.2023; however, no contracts will be concluded by AOK Nordost before 04.07.2023. For a later start of the contract, the submission deadline for the offers is the 5th of the respective previous month. (Example: Contract start 01.09.2023; Deadline for submission of the offer: 05.08.2023).

Should AOK Nordost grant an exclusive surcharge for the active substance/active ingredient combination (s) within the framework of an open procedure during the contract period, the contractual provisions concluded within the framework of this publication apply. This publication is not the award of a public contract within the meaning of the procurement coordination directive 2014/24/EU of the European Parliament and the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, this form of contract notice is used. The resulting conceptual requirements, such as the process name of open procedure, are solely due to the use of this announcement form and the publication platform. This does not entail any further significance, in particular a submission to public procurement regulations, unless they are obligated for legal reasons. The orders placed are announced exclusively via the following link: https://www.aok.de/gp/apotheker-pharmazeutisches-personal/arzneimittelrabattvertraege/arzneimittelrabattvertraege-worum-geht-es.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active substances/drug combinations within the framework of a so-called open house procedure. Under specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to conclude or join a discount contract in accordance with Section 130a (8) SGB V for the above-mentioned active substance/active ingredient combination. After registration, interested pharmaceutical companies can download the procurement documents (participation documents and contract) at: https://www.dtvp.de/Satellite/notice/documents.

The procedures referred to in Section I: Contracting authorities, item 1.3.) Communication for the purpose of unrestricted and complete, toll-free access to the order documents does not exist. Information can only be obtained via your registration on the “DTVP” award platform, under the communication tab. Information and answers about other bodies are not binding.

A prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the required procedural documents completely completed and signed. Any pharmaceutical company that meets the eligibility requirements and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. Accession or conclusion of the contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The contract can only start on the first day of each month. The earliest start date of the contract is 01.08.2023. Based on this, the contract period is a maximum of 24 months. The contract ends no later than 31.07.2025, regardless of the date of conclusion of the contract. The offer must be available by 23.06.2023 at the latest if the contract starts on 01.08.2023; however, no contracts will be concluded by AOK Nordost before 04.07.2023. For a later start of the contract, the submission deadline for the offers is the 5th of the respective previous month. (Example: Contract start 01.09.2023; Deadline for submission of the offer: 05.08.2023).

Should AOK Nordost grant an exclusive surcharge for the active substance/active ingredient combination (s) within the framework of an open procedure during the contract period, the contractual provisions concluded within the framework of this publication apply. This publication is not the award of a public contract within the meaning of the procurement coordination directive 2014/24/EU of the European Parliament and the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, this form of contract notice is used. The resulting conceptual requirements, such as the process name of open procedure, are solely due to the use of this announcement form and the publication platform. This does not entail any further significance, in particular a submission to public procurement regulations, unless they are obligated for legal reasons. The orders placed are announced exclusively via the following link: https://www.aok.de/gp/apotheker-pharmazeutisches-personal/arzneimittelrabattvertraege/arzneimittelrabattvertraege-worum-geht-es.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active substances/drug combinations within the framework of a so-called open house procedure. Under specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to conclude or join a discount contract in accordance with Section 130a (8) SGB V for the above-mentioned active substance/active ingredient combination. After registration, interested pharmaceutical companies can download the procurement documents (participation documents and contract) at: https://www.dtvp.de/Satellite/notice/documents.

The procedures referred to in Section I: Contracting authorities, item 1.3.) Communication for the purpose of unrestricted and complete, toll-free access to the order documents does not exist. Information can only be obtained via your registration on the “DTVP” award platform, under the communication tab. Information and answers about other bodies are not binding.

A prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the required procedural documents completely completed and signed. Any pharmaceutical company that meets the eligibility requirements and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. Accession or conclusion of the contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The contract can only start on the first day of each month. The earliest start date of the contract is 01.08.2023. Based on this, the contract period is a maximum of 24 months. The contract ends no later than 31.07.2025, regardless of the date of conclusion of the contract. The offer must be available by 23.06.2023 at the latest if the contract starts on 01.08.2023; however, no contracts will be concluded by AOK Nordost before 04.07.2023. For a later start of the contract, the submission deadline for the offers is the 5th of the respective previous month. (Example: Contract start 01.09.2023; Deadline for submission of the offer: 05.08.2023).

Should AOK Nordost grant an exclusive surcharge for the active substance/active ingredient combination (s) within the framework of an open procedure during the contract period, the contractual provisions concluded within the framework of this publication apply. This publication is not the award of a public contract within the meaning of the procurement coordination directive 2014/24/EU of the European Parliament and the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, this form of contract notice is used. The resulting conceptual requirements, such as the process name of open procedure, are solely due to the use of this announcement form and the publication platform. This does not entail any further significance, in particular a submission to public procurement regulations, unless they are obligated for legal reasons. The orders placed are announced exclusively via the following link: https://www.aok.de/gp/apotheker-pharmazeutisches-personal/arzneimittelrabattvertraege/arzneimittelrabattvertraege-worum-geht-es.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active substances/drug combinations within the framework of a so-called open house procedure. Under specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to conclude or join a discount contract in accordance with Section 130a (8) SGB V for the above-mentioned active substance/active ingredient combination. After registration, interested pharmaceutical companies can download the procurement documents (participation documents and contract) at: https://www.dtvp.de/Satellite/notice/documents.

The procedures referred to in Section I: Contracting authorities, item 1.3.) Communication for the purpose of unrestricted and complete, toll-free access to the order documents does not exist. Information can only be obtained via your registration on the “DTVP” award platform, under the communication tab. Information and answers about other bodies are not binding.

A prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the required procedural documents completely completed and signed. Any pharmaceutical company that meets the eligibility requirements and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. Accession or conclusion of the contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The contract can only start on the first day of each month. The earliest start date of the contract is 01.08.2023. Based on this, the contract period is a maximum of 24 months. The contract ends no later than 31.07.2025, regardless of the date of conclusion of the contract. The offer must be available by 23.06.2023 at the latest if the contract starts on 01.08.2023; however, no contracts will be concluded by AOK Nordost before 04.07.2023. For a later start of the contract, the submission deadline for the offers is the 5th of the respective previous month. (Example: Contract start 01.09.2023; Deadline for submission of the offer: 05.08.2023).

Should AOK Nordost grant an exclusive surcharge for the active substance/active ingredient combination (s) within the framework of an open procedure during the contract period, the contractual provisions concluded within the framework of this publication apply. This publication is not the award of a public contract within the meaning of the procurement coordination directive 2014/24/EU of the European Parliament and the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, this form of contract notice is used. The resulting conceptual requirements, such as the process name of open procedure, are solely due to the use of this announcement form and the publication platform. This does not entail any further significance, in particular a submission to public procurement regulations, unless they are obligated for legal reasons. The orders placed are announced exclusively via the following link: https://www.aok.de/gp/apotheker-pharmazeutisches-personal/arzneimittelrabattvertraege/arzneimittelrabattvertraege-worum-geht-es.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active substances/drug combinations within the framework of a so-called open house procedure. Under specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to conclude or join a discount contract in accordance with Section 130a (8) SGB V for the above-mentioned active substance/active ingredient combination. After registration, interested pharmaceutical companies can download the procurement documents (participation documents and contract) at: https://www.dtvp.de/Satellite/notice/documents.

The procedures referred to in Section I: Contracting authorities, item 1.3.) Communication for the purpose of unrestricted and complete, toll-free access to the order documents does not exist. Information can only be obtained via your registration on the “DTVP” award platform, under the communication tab. Information and answers about other bodies are not binding.

A prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the required procedural documents completely completed and signed. Any pharmaceutical company that meets the eligibility requirements and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. Accession or conclusion of the contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The contract can only start on the first day of each month. The earliest start date of the contract is 01.08.2023. Based on this, the contract period is a maximum of 24 months. The contract ends no later than 31.07.2025, regardless of the date of conclusion of the contract. The offer must be available by 23.06.2023 at the latest if the contract starts on 01.08.2023; however, no contracts will be concluded by AOK Nordost before 04.07.2023. For a later start of the contract, the submission deadline for the offers is the 5th of the respective previous month. (Example: Contract start 01.09.2023; Deadline for submission of the offer: 05.08.2023).

Should AOK Nordost grant an exclusive surcharge for the active substance/active ingredient combination (s) within the framework of an open procedure during the contract period, the contractual provisions concluded within the framework of this publication apply. This publication is not the award of a public contract within the meaning of the procurement coordination directive 2014/24/EU of the European Parliament and the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, this form of contract notice is used. The resulting conceptual requirements, such as the process name of open procedure, are solely due to the use of this announcement form and the publication platform. This does not entail any further significance, in particular a submission to public procurement regulations, unless they are obligated for legal reasons. The orders placed are announced exclusively via the following link: https://www.aok.de/gp/apotheker-pharmazeutisches-personal/arzneimittelrabattvertraege/arzneimittelrabattvertraege-worum-geht-es.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active substances/drug combinations within the framework of a so-called open house procedure. Under specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to conclude or join a discount contract in accordance with Section 130a (8) SGB V for the above-mentioned active substance/active ingredient combination. After registration, interested pharmaceutical companies can download the procurement documents (participation documents and contract) at: https://www.dtvp.de/Satellite/notice/documents.

The procedures referred to in Section I: Contracting authorities, item 1.3.) Communication for the purpose of unrestricted and complete, toll-free access to the order documents does not exist. Information can only be obtained via your registration on the “DTVP” award platform, under the communication tab. Information and answers about other bodies are not binding.

A prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the required procedural documents completely completed and signed. Any pharmaceutical company that meets the eligibility requirements and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. Accession or conclusion of the contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The contract can only start on the first day of each month. The earliest start date of the contract is 01.08.2023. Based on this, the contract period is a maximum of 24 months. The contract ends no later than 31.07.2025, regardless of the date of conclusion of the contract. The offer must be available by 23.06.2023 at the latest if the contract starts on 01.08.2023; however, no contracts will be concluded by AOK Nordost before 04.07.2023. For a later start of the contract, the submission deadline for the offers is the 5th of the respective previous month. (Example: Contract start 01.09.2023; Deadline for submission of the offer: 05.08.2023).

Should AOK Nordost grant an exclusive surcharge for the active substance/active ingredient combination (s) within the framework of an open procedure during the contract period, the contractual provisions concluded within the framework of this publication apply. This publication is not the award of a public contract within the meaning of the procurement coordination directive 2014/24/EU of the European Parliament and the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, this form of contract notice is used. The resulting conceptual requirements, such as the process name of open procedure, are solely due to the use of this announcement form and the publication platform. This does not entail any further significance, in particular a submission to public procurement regulations, unless they are obligated for legal reasons. The orders placed are announced exclusively via the following link: https://www.aok.de/gp/apotheker-pharmazeutisches-personal/arzneimittelrabattvertraege/arzneimittelrabattvertraege-worum-geht-es.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active substances/drug combinations within the framework of a so-called open house procedure. Under specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to conclude or join a discount contract in accordance with Section 130a (8) SGB V for the above-mentioned active substance/active ingredient combination. After registration, interested pharmaceutical companies can download the procurement documents (participation documents and contract) at: https://www.dtvp.de/Satellite/notice/documents.

The procedures referred to in Section I: Contracting authorities, item 1.3.) Communication for the purpose of unrestricted and complete, toll-free access to the order documents does not exist. Information can only be obtained via your registration on the “DTVP” award platform, under the communication tab. Information and answers about other bodies are not binding.

A prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the required procedural documents completely completed and signed. Any pharmaceutical company that meets the eligibility requirements and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. Accession or conclusion of the contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The contract can only start on the first day of each month. The earliest start date of the contract is 01.08.2023. Based on this, the contract period is a maximum of 24 months. The contract ends no later than 31.07.2025, regardless of the date of conclusion of the contract. The offer must be available by 23.06.2023 at the latest if the contract starts on 01.08.2023; however, no contracts will be concluded by AOK Nordost before 04.07.2023. For a later start of the contract, the submission deadline for the offers is the 5th of the respective previous month. (Example: Contract start 01.09.2023; Deadline for submission of the offer: 05.08.2023).

Should AOK Nordost grant an exclusive surcharge for the active substance/active ingredient combination (s) within the framework of an open procedure during the contract period, the contractual provisions concluded within the framework of this publication apply. This publication is not the award of a public contract within the meaning of the procurement coordination directive 2014/24/EU of the European Parliament and the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, this form of contract notice is used. The resulting conceptual requirements, such as the process name of open procedure, are solely due to the use of this announcement form and the publication platform. This does not entail any further significance, in particular a submission to public procurement regulations, unless they are obligated for legal reasons. The orders placed are announced exclusively via the following link: https://www.aok.de/gp/apotheker-pharmazeutisches-personal/arzneimittelrabattvertraege/arzneimittelrabattvertraege-worum-geht-es.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active substances/drug combinations within the framework of a so-called open house procedure. Under specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to conclude or join a discount contract in accordance with Section 130a (8) SGB V for the above-mentioned active substance/active ingredient combination. After registration, interested pharmaceutical companies can download the procurement documents (participation documents and contract) at: https://www.dtvp.de/Satellite/notice/documents.

The procedures referred to in Section I: Contracting authorities, item 1.3.) Communication for the purpose of unrestricted and complete, toll-free access to the order documents does not exist. Information can only be obtained via your registration on the “DTVP” award platform, under the communication tab. Information and answers about other bodies are not binding.

A prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the required procedural documents completely completed and signed. Any pharmaceutical company that meets the eligibility requirements and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. Accession or conclusion of the contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The contract can only start on the first day of each month. The earliest start date of the contract is 01.08.2023. Based on this, the contract period is a maximum of 24 months. The contract ends no later than 31.07.2025, regardless of the date of conclusion of the contract. The offer must be available by 23.06.2023 at the latest if the contract starts on 01.08.2023; however, no contracts will be concluded by AOK Nordost before 04.07.2023. For a later start of the contract, the submission deadline for the offers is the 5th of the respective previous month. (Example: Contract start 01.09.2023; Deadline for submission of the offer: 05.08.2023).

Should AOK Nordost grant an exclusive surcharge for the active substance/active ingredient combination (s) within the framework of an open procedure during the contract period, the contractual provisions concluded within the framework of this publication apply. This publication is not the award of a public contract within the meaning of the procurement coordination directive 2014/24/EU of the European Parliament and the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, this form of contract notice is used. The resulting conceptual requirements, such as the process name of open procedure, are solely due to the use of this announcement form and the publication platform. This does not entail any further significance, in particular a submission to public procurement regulations, unless they are obligated for legal reasons. The orders placed are announced exclusively via the following link: https://www.aok.de/gp/apotheker-pharmazeutisches-personal/arzneimittelrabattvertraege/arzneimittelrabattvertraege-worum-geht-es.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active substances/drug combinations within the framework of a so-called open house procedure. Under specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to conclude or join a discount contract in accordance with Section 130a (8) SGB V for the above-mentioned active substance/active ingredient combination. After registration, interested pharmaceutical companies can download the procurement documents (participation documents and contract) at: https://www.dtvp.de/Satellite/notice/documents.

The procedures referred to in Section I: Contracting authorities, item 1.3.) Communication for the purpose of unrestricted and complete, toll-free access to the order documents does not exist. Information can only be obtained via your registration on the “DTVP” award platform, under the communication tab. Information and answers about other bodies are not binding.

A prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the required procedural documents completely completed and signed. Any pharmaceutical company that meets the eligibility requirements and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. Accession or conclusion of the contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The contract can only start on the first day of each month. The earliest start date of the contract is 01.08.2023. Based on this, the contract period is a maximum of 24 months. The contract ends no later than 31.07.2025, regardless of the date of conclusion of the contract. The offer must be available by 23.06.2023 at the latest if the contract starts on 01.08.2023; however, no contracts will be concluded by AOK Nordost before 04.07.2023. For a later start of the contract, the submission deadline for the offers is the 5th of the respective previous month. (Example: Contract start 01.09.2023; Deadline for submission of the offer: 05.08.2023).

Should AOK Nordost grant an exclusive surcharge for the active substance/active ingredient combination (s) within the framework of an open procedure during the contract period, the contractual provisions concluded within the framework of this publication apply. This publication is not the award of a public contract within the meaning of the procurement coordination directive 2014/24/EU of the European Parliament and the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, this form of contract notice is used. The resulting conceptual requirements, such as the process name of open procedure, are solely due to the use of this announcement form and the publication platform. This does not entail any further significance, in particular a submission to public procurement regulations, unless they are obligated for legal reasons. The orders placed are announced exclusively via the following link: https://www.aok.de/gp/apotheker-pharmazeutisches-personal/arzneimittelrabattvertraege/arzneimittelrabattvertraege-worum-geht-es.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active substances/drug combinations within the framework of a so-called open house procedure. Under specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to conclude or join a discount contract in accordance with Section 130a (8) SGB V for the above-mentioned active substance/active ingredient combination. After registration, interested pharmaceutical companies can download the procurement documents (participation documents and contract) at: https://www.dtvp.de/Satellite/notice/documents.

The procedures referred to in Section I: Contracting authorities, item 1.3.) Communication for the purpose of unrestricted and complete, toll-free access to the order documents does not exist. Information can only be obtained via your registration on the “DTVP” award platform, under the communication tab. Information and answers about other bodies are not binding.

A prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the required procedural documents completely completed and signed. Any pharmaceutical company that meets the eligibility requirements and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. Accession or conclusion of the contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The contract can only start on the first day of each month. The earliest start date of the contract is 01.08.2023. Based on this, the contract period is a maximum of 24 months. The contract ends no later than 31.07.2025, regardless of the date of conclusion of the contract. The offer must be available by 23.06.2023 at the latest if the contract starts on 01.08.2023; however, no contracts will be concluded by AOK Nordost before 04.07.2023. For a later start of the contract, the submission deadline for the offers is the 5th of the respective previous month. (Example: Contract start 01.09.2023; Deadline for submission of the offer: 05.08.2023).

Should AOK Nordost grant an exclusive surcharge for the active substance/active ingredient combination (s) within the framework of an open procedure during the contract period, the contractual provisions concluded within the framework of this publication apply. This publication is not the award of a public contract within the meaning of the procurement coordination directive 2014/24/EU of the European Parliament and the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, this form of contract notice is used. The resulting conceptual requirements, such as the process name of open procedure, are solely due to the use of this announcement form and the publication platform. This does not entail any further significance, in particular a submission to public procurement regulations, unless they are obligated for legal reasons. The orders placed are announced exclusively via the following link: https://www.aok.de/gp/apotheker-pharmazeutisches-personal/arzneimittelrabattvertraege/arzneimittelrabattvertraege-worum-geht-es.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active substances/drug combinations within the framework of a so-called open house procedure. Under specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to conclude or join a discount contract in accordance with Section 130a (8) SGB V for the above-mentioned active substance/active ingredient combination. After registration, interested pharmaceutical companies can download the procurement documents (participation documents and contract) at: https://www.dtvp.de/Satellite/notice/documents.

The procedures referred to in Section I: Contracting authorities, item 1.3.) Communication for the purpose of unrestricted and complete, toll-free access to the order documents does not exist. Information can only be obtained via your registration on the “DTVP” award platform, under the communication tab. Information and answers about other bodies are not binding.

A prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the required procedural documents completely completed and signed. Any pharmaceutical company that meets the eligibility requirements and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. Accession or conclusion of the contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The contract can only start on the first day of each month. The earliest start date of the contract is 01.08.2023. Based on this, the contract period is a maximum of 24 months. The contract ends no later than 31.07.2025, regardless of the date of conclusion of the contract. The offer must be available by 23.06.2023 at the latest if the contract starts on 01.08.2023; however, no contracts will be concluded by AOK Nordost before 04.07.2023. For a later start of the contract, the submission deadline for the offers is the 5th of the respective previous month. (Example: Contract start 01.09.2023; Deadline for submission of the offer: 05.08.2023).

Should AOK Nordost grant an exclusive surcharge for the active substance/active ingredient combination (s) within the framework of an open procedure during the contract period, the contractual provisions concluded within the framework of this publication apply. This publication is not the award of a public contract within the meaning of the procurement coordination directive 2014/24/EU of the European Parliament and the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, this form of contract notice is used. The resulting conceptual requirements, such as the process name of open procedure, are solely due to the use of this announcement form and the publication platform. This does not entail any further significance, in particular a submission to public procurement regulations, unless they are obligated for legal reasons. The orders placed are announced exclusively via the following link: https://www.aok.de/gp/apotheker-pharmazeutisches-personal/arzneimittelrabattvertraege/arzneimittelrabattvertraege-worum-geht-es.